Emergent Biosolutions’ Q2 Earnings Call: NARCAN Market Flatness vs. Long-Term Growth, Shifting Revenue Drivers

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $234M, above the $185M high end of guidance
• Gross Margin: 58% adjusted gross margin, up from 49% in Q2 2025
• Operating Margin: 41% adjusted EBITDA margin, compared with 23% margin in Q2 prior year

Guidance:

• Full-year 2026 total revenue guidance revised to $645M-$675M from prior $720M-$760M.
• GAAP net loss expected in range of -$245M to -$225M, including non-cash impairment charge.
• Adjusted net income guidance of $10M to $30M.
• Adjusted EBITDA guidance revised to $130M-$150M from prior $155M-$175M.
• Adjusted gross margin guidance of 42%-44%.
• Q3 total revenue expected between $110M and $130M.

Business Commentary:

Strong Financial Performance in Q2 2026:

• Emergent BioSolutions reported Q2 revenue of $234 million, significantly exceeding the high end of its guidance range and internal expectations.
• The company delivered Q2 adjusted EBITDA of $97 million with a 41% margin, compared to $33 million and a 23% margin in the prior year period.
• This strong performance was primarily driven by accelerated deliveries and contract activity in the medical countermeasures (MCM) segment, particularly related to ACAM2000 and botulism antitoxin.

Naloxone Market Challenges and Restructuring:

• The company's naloxone business, led by the NARCAN brand, is facing increased competitive pressure, with new market entrants and aggressive pricing affecting sales expectations.
• In response, Emergent is implementing restructuring actions that are expected to yield annualized savings of approximately $40 million, including a workforce reduction of about 90 positions and the closure of two wet laboratories.
• The restructuring aims to align resources with current business realities and improve the company's overall cost structure amid the evolving market dynamics.

Medical Countermeasures Segment Performance:

• MCM revenue reached $168 million in Q2, the highest second-quarter revenue since 2020, with international sales representing approximately 20% of the total first-half MCM revenues.
• This performance was supported by contract modifications and international orders, including a $52.7 million contract for ACAM2000 and a $64.5 million contract for botulism antitoxin.
• The strength in the MCM segment is attributed to continued partnership with the U.S. government and increasing international engagement due to rising public health threats like Ebola.

Guidance Revision and NARCAN Impairment:

• Full-year 2026 total revenue guidance was revised to a range of $645 million-$675 million, down from the previous range of $720 million-$760 million, primarily due to lower expected commercial revenue from the naloxone segment.
• A non-cash impairment charge of approximately $191 million was recorded for the NARCAN product line, reflecting updated assessments of expected future cash flows amid increased competitive and pricing pressures.
• Despite the guidance revision, the company remains focused on cash generation, disciplined capital management, and executing its cost savings program to support profitability and liquidity.

Sentiment Analysis:

Overall Tone: Negative

• "We have responded by implementing actions to drive greater efficiency and cost savings as we exit this year..." "This accounting adjustment reflects our updated assessment of the product’s expected future cash flows in the context of current market dynamics, including pricing and competitive factors." "We are taking decisive action now to address NARCAN business realities..."

Q&A:

• Question from Raghuram Selvaraju (H.C. Wainwright & Co.): Provide granularity on initiatives to slow NARCAN sales erosion and leverage brand recognition against next-gen fentanyl analogues; insight into strategic thinking behind reorientation away from basic R&D and sense of emergent trends in MCM contract procurement demands outside the US.
  Response: Initiatives include brand strength, new innovations (carrying case, multi-packs), and recognizing market share pressure. R&D remains important but will be managed under a unified growth organization for faster, better capital allocation. Seeing increased government concern over bioterrorism and AI risks, and plans to collaborate on preparedness.

• Question from Jessica Fye (JPMorgan): Outline what’s in other revenue and how sustainable; elaborate on naloxone market and price/volume expectations for NARCAN; and understand if revenue guidance update is entirely NARCAN related.
  Response: Other revenue driven by BOT delivery; market remains strong but with competitive price pressures, expects market to be flat and additional price erosion, aiming to maintain share. Guidance reduction is primarily due to lower commercial revenue from naloxone.

• Question from Alex Kelsey (Wells Fargo): Clarify nature of July AR collection and pro forma cash; and target of $75M debt repurchase authorization.
  Response: AR collection was from normal course deliveries, not securitization; cash pro forma is closer to $285M. Debt repurchase authorization is specifically for senior unsecured notes.

Contradiction Point 1

NARCAN Market Outlook

Inconsistent guidance on total naloxone market growth versus flatness.

Jessica Fye (JPMorgan) - Jessica Fye (JPMorgan)

2026Q2: Expect additional price erosion but anticipate the total naloxone market to be relatively flat. - Joe Papa(CEO) and Rich Lindahl(CFO)

What are the current naloxone market dynamics and expected price/volume trends for NARCAN for the remainder of the year and beyond? - Jessica Fye (JPMorgan)

20260501-2026 Q1: The naloxone business is expected to be flat to slightly up for 2026... Long-term market growth is anticipated due to ongoing opioid overdose deaths... - Joseph Papa(CEO)

Contradiction Point 2

Revenue Guidance Drivers

The primary driver for guidance revision shifts from broad portfolio performance to being solely NARCAN-related.

Is the revenue guidance update entirely driven by NARCAN, or is there upside from other business lines? - Is the revenue guidance update entirely due to NARCAN, or is there offsetting upside from other business lines?

2026Q2: Primary driver is lower expected commercial revenue in H2 2026 due to NARCAN pressures. - Rich Lindahl(CFO) and Joe Papa(CEO)

Unspecified (from prior call context) - Unspecified (from prior call context)

20260501-2026 Q1: The entire portfolio is being evaluated, not just one program... This is a portfolio decision. - Joseph Papa(CEO) [Implied from context of prior guidance revision discussion]

Contradiction Point 3

NARCAN's Competitive Outlook and Market Dynamics

NARCAN's market share trajectory and competitive response shift from growth to significant pressure.

Raghuram Selvaraju (H.C. Wainwright & Co.) - Raghuram Selvaraju (H.C. Wainwright & Co.)

2026Q2: NARCAN remains the gold standard with over 50% market share... Acknowledge **increased competitive pressure and expected price erosion** due to new entrants. - Joe Papa(CEO)

What specific initiatives are planned to address NARCAN's sales decline and counter new fentanyl analogues? - Jessica Fye (JPMorgan Chase & Co, Research Division)

2026Q1: NARCAN is expected to maintain leading market share and competitive pricing. - Joseph Papa(CEO)

Contradiction Point 4

Strategic Focus on R&D and Business Development

R&D's strategic importance appears to be downplayed in favor of a new portfolio management structure.

Raghuram Selvaraju (H.C. Wainwright & Co.) - Raghuram Selvaraju (H.C. Wainwright & Co.)

2026Q2: Unifying **R&D and business development under one team leader**... to enable faster, more informed portfolio decisions. - Joe Papa(CEO)

What is the strategic thinking behind shifting focus from basic R&D and how will resources be redeployed, such as toward in-licensing? - Raghuram Selvaraju (H.C. Wainwright & Co, LLC, Research Division)

2026Q1: The partnership [with SAB Biotherapeutics] is primarily based on aligning **manufacturing technology capabilities** rather than a broad strategic shift into a new therapeutic area. - Joseph Papa(CEO)

Contradiction Point 5

Nature of "Other Revenue" Driver

Contradictory explanations for the primary driver of "other revenue" growth.

Jessica Fye (JPMorgan) - Jessica Fye (JPMorgan)

2026Q2: Primarily driven by a **significant delivery of the botulism antitoxin (BAT) product** in Q3 2025, which contributed to year-over-year growth. - Joe Papa and Rich Lindahl

What caused the year-over-year increase in "other revenue," and is it sustainable? - Operator (Conference Call)

20260227-2025 Q4: The presentation was clear, straightforward, and answered questions that people had anticipated. - Joseph Papa(CEO)